Abstract:Background Humans with inactivating mutations in growth hormone receptor (GHR) have lower rates of cancer, including prostate cancer. Similarly, mice with inactivating Ghr mutations are protected from prostatic intraepithelial neoplasia in the C3(1)/TAg prostate cancer model. However, gaps in clinical relevance in those models persist. The current study addresses these gaps and the ongoing role of Ghr in prostate cancer using loss‐of‐function and gain‐of‐function models. Methods Conditional Ghr inactivation was achieved in the C3(1)/TAg model by employing a tamoxifen‐inducible Cre and a prostate‐specific Cre. In parallel, a transgenic GH antagonist was also used. Pathology, proliferation, and gene expression of 6‐month old mouse prostates were assessed. Analysis of The Cancer Genome Atlas data was conducted to identify GHR overexpression in a subset of human prostate cancers. Ghr overexpression was modeled in PTEN‐P2 and TRAMP‐C2 mouse prostate cancer cells using stable transfectants. The growth, proliferation, and gene expression effects of Ghr overexpression was assessed in vitro and in vivo. Results Loss‐of‐function for Ghr globally or in prostatic epithelial cells reduced proliferation and stratification of the prostatic epithelium in the C3(1)/TAg model. Genes and gene sets involved in the immune system and tumorigenesis, for example, were dysregulated upon global Ghr disruption. Analysis of The Cancer Genome Atlas revealed higher GHR expression in human prostate cancers with ERG‐fusion genes or ETV1‐fusion genes. Modeling the GHR overexpression observed in these human prostate cancers by overexpressing Ghr in mouse prostate cancer cells with mutant Pten or T‐antigen driver genes increased proliferation of prostate cancer cells in vitro and in vivo. Ghr overexpression regulated the expression of multiple genes oppositely to Ghr loss‐of‐function models. Conclusions Loss‐of‐function and gain‐of‐function Ghr models, including prostatic epithelial cell specific alterations in Ghr, altered proliferation, and gene expression. These data suggest that changes in GHR activity in human prostatic epithelial cells play a role in proliferation and gene regulation in prostate cancer, suggesting the potential for disrupting GH signaling, for example by the FDA approved GH antagonist pegvisomant, may be beneficial in treating prostate cancer.

Growth Hormone Receptor Regulation in Cancer and Chronic Diseases

The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects

Structural Basis for Activation of the Growth Hormone-Releasing Hormone Receptor.

Growth Hormone and Cancer: an Update on Progress

Growth hormone-releasing hormone and cancer

Growth Hormone Signaling in Human T47D Breast Cancer Cells: Potential Role for a Growth Hormone Receptor-Prolactin Receptor Complex.

Growth hormone receptor signaling is dispensable for HSC function and aging

The development of growth hormone-releasing hormone analogs: Therapeutic advances in cancer, regenerative medicine, and metabolic disorders

Growth-hormone signal transduction

Roles of Growth Hormone-Dependent JAK-STAT5 and Lyn Kinase Signaling in Determining Lifespan and Cancer Incidence

Growth Hormone and Aging: New Findings

Growth hormone-releasing hormone and its analogues in health and disease

Expression of growth hormone and its receptor in chronic atrophic gastritis and its clinical significance.

Conditional gene regulation models demonstrate a pro‐proliferative role for growth hormone receptor in prostate cancer

Human growth hormone and human prolactin function as autocrine/paracrine promoters of progression of hepatocellular carcinoma.

GHRH and the prostate

A role for JAK2 in mediating cell surface GHR-PRLR interaction

Research Advances in Growth Hormone Receptor

Tumour-Derived Human Growth Hormone As a Therapeutic Target in Oncology.

Identification of Small-Molecule Antagonists Targeting the Growth Hormone Releasing Hormone Receptor (GHRHR)

The Growth-Hormone Receptor During Development